Our people

Meet two women at the forefront of our HIV research

Two esteemed scientists share their motivations and hopes for the future of HIV research

July 19, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

The field of HIV research has changed drastically in the past 40 years. In that time, we’ve evolved from helping people with HIV struggle to survive to seeing them fully thrive. Now we’re chasing a cure for HIV.

On top of a shift in focus, we’ve also seen a transformation in those who occupy the research space: more and more women are joining the fight.

We spoke with two of our own researchers who are leading the charge, Bonnie Howell, Ph.D., and Rebeca Plank, M.D., about what drives them, what’s changed, and what’s next in the HIV research landscape.

What drew you to HIV research?

Rebeca Plank: I think my interest was first sparked at home by my parents, who actually met doing public health work in Chile. But it’s funny, despite that background, I wasn’t pre-med in college. I was an anthropology major. But during my senior thesis, I worked on a project around HIV prevention messaging. That stuck with me.

Quote from Rebeca Plank "I was inspired to pursue science and population health where I continuously ask the question, 'How can we make it easier for people to improve their health?'"

This includes making interventions relevant and accessible.

Bonnie Howell: I can relate to that. I started working in HIV research after years of working in oncology and quickly recognized the unmet medical need. I realized that a lot of what I learned about cancer research could be applied to HIV as well.

I became passionate about HIV research because I saw it as an opportunity to change the storyline and apply my oncology experience to this different field.

In your mind, what’s been the biggest shift in HIV care?

RP: I think the vast shift can be summed up by what I saw in med school. I was studying in San Francisco between 1996–2001, and I watched an inpatient hospital ward go from a place that housed critically ill people to a general medicine ward full of people rightfully expecting to feel better and go back home.

And that’s all due to the fast and impactful medical innovations — such as antiretrovirals to treat HIV — that helped save so many lives.

In a field that’s been historically male dominated, how does it feel to be a female in science and HIV research?

BH: My experience is definitely unique because I’ve been at MSD for my entire career — and I’ve been constantly surrounded by powerful and brilliant women. It’s been a privilege to be a part of a company that champions diversity and inclusion and has empowered me to roll up my sleeves and contribute day in and day out to this important mission.

And I’m grateful for the chance to continue to add to the legacy MSD has established for itself in HIV — helping to change the way HIV has been treated since the start of the epidemic.

RP: That said, there are still challenges facing women in HIV research. As a med student and also as a resident, it struck me that, looking around the hospital, there were relatively few women who were further along in their careers. It can be so important to see people succeeding who look like you, as role models and mentors — they show you what’s possible.

BH: I completely agree. I also count myself lucky that I was mentored by female leaders who charted the course and were instrumental in increasing the number of women in research. Now I pay that forward and mentor the next generation of female researchers — especially those pursuing HIV.

Why do you think gender diversity is critical in HIV research?

BH: Globally, women bear a huge brunt of this epidemic. A study in 2021 showed that 54% of all people with HIV are women and girls. Yet women are significantly under-represented in HIV clinical trials. We need to change that.

Equally important is making sure that the female perspective is represented within the HIV research community, so women with HIV can have advocates who share and understand their unique female experiences.

RP: Prior to joining MSD, during my time doing field work in Kenya and Botswana, I learned a lot about the nuances and unique hardships of the female HIV experience. Globally, advocating for herself may not always be a woman’s first priority. Not to mention that the stigma of HIV is still too prevalent around the world, which may make it harder to seek care.

Quote from Bonnie Howell "It's so important to be a woman in HIV research. My goal is to represent women with HIV and be their voice and champoin."

What advancement in HIV research do you hope to see during your lifetimes?

BH: A cure. Whether that’s eradicating HIV from patients’ bodies or remission, where the virus still exists in the body but is controlled without lifelong treatment.

RP: And then getting this cure — as well as other treatments and better methods for HIV prevention — to people in need, in the manner they need it. Access remains a huge issue, and part of that is the mode of treatment such as frequency of pills or injections. We hear consistently that having discreet treatment and prevention options would be critical.

What gives you the most hope?

RP: So much can evolve in a single generation. These young women we’re working to help, someday they’ll be grandmothers. By empowering them with knowledge and by continuing our work in HIV, we hope to protect future generations.

BH: The HIV community is so passionate and engaged, and we’re designing studies and treatments with those affected in mind. I’m excited to see what the future brings.

Innovation

Podcast: Why neuroscience is the ‘final frontier’

Listen as specialists from MSD discuss what they’re most excited about in researching potential treatments for neurologic disorders

July 13, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Our scientists are revolutionizing how we discover and develop treatments to address unmet medical needs in a number of areas, including neuroscience.

“It’s sort of like the final frontier,” said Joe Herring, scientific AVP, clinical research, in our new podcast. “You’re going off into space to try to figure out how to do very difficult things.”

For more, listen in as Herring sits down with MSD clinical research team senior principal scientists Yuki Mukai and Ari Merola as well as business development director Paige Lacatena to explore today’s breakthroughs and challenges in the field of neuroscience.

Listen to the podcast

Read the full transcript

Explore careers in R&D at MSD

man and woman MSD scientists

Careers

Are you interested in a career in R&D?

Our people

Podcast: Meet the dealmakers 

MSD’s business development and licensing team explain how they identify new opportunities to strengthen our robust R&D pipeline  

June 5, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

It takes a special kind of talent to find and secure the right deals to keep us at the forefront of innovation. Leaders from our business development and licensing team sat down to discuss how their work is a key component to building and maintaining a strong pipeline.  

Here’s what you need to know:  

01.

Harnessing our legacy

Our reputation for using leading-edge science can make business development connections easier, explains Lizabeth Leveille, vice president, business development.


02.

The speed and determination to get it done

Elizabeth Naldi-Jacob, vice president, business development, knows that having a direct line of reporting to the top is what sets MSD apart as a potential partner. 


03.

Balancing the internal and the external  

We have a one pipeline mindset, and each asset receives the same focus and rigor whether it comes from inside our company or out, says Christopher Mortko, vice president, business development. 


04.

Working hand-in-hand with our scientists  

Grace Han McMahon, associate vice president, business development, explains why engaging our internal science leaders is crucial to making the right deals. 


05.

What we’re interested in (and why it’s everything) 

Our panelists discuss why we focus on five key areas — and when we’re willing to look beyond them.


Great partnerships begin with great conversation. Learn more about how discovery & development and licensing shape the future of MSD.  

For more, check out the full podcast: 

MSD BD&L

Read the transcript

Our people

Here for Good: Bridging the gap between bedside and bench

Members of MSD’s lung cancer clinical development team say working in the hospital inspired their drive to innovate for patients

May 19, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Dr. Ayman Samkari remembers how treating patients during his medical school rotations brought him face to face with the unmet needs of people with cancer. He learned to listen to what matters for patients beyond their diagnoses, and he sought new ways to make a greater impact as an oncologist.

Watch Samkari and Dr. Nazly Shariati discuss their passion for their work:

Two colleagues walk and talk

“Even though I enjoyed every moment of practicing medicine and treating patients with cancer, I had the question at the back of my mind: How can I do things differently? How can I improve patient outcomes?” recalled Samkari, who now works for MSD as executive director in oncology clinical development. “That’s what drove me to pursue my career in clinical research, where I could help patients on a larger scale.”

And after 25 years as a surgeon, when a hand ailment ultimately sidelined her in the operating room, Dr. Nazly Shariati found that research was another avenue to help more patients.

article quote image

“MSD allowed me to not only fulfill my goals in life and my career but continue on my path to have an impact on patients’ lives.”

— Dr. Nazly Shariati

Senior principal scientist in oncology clinical development

From careers in clinical care to careers in research

Samkari’s background as an oncologist, and Shariati’s as a surgeon, have informed their work in our lung cancer clinical development program. All too familiar with the challenges of treating patients with advanced disease, Samkari and Shariati are shifting their research to investigating lung cancer at its earlier stages, before it has spread, when it’s more likely to be successfully treated.

When she was a cardiothoracic surgeon, Shariati often felt a sinking feeling whenever a patient’s lung cancer would return, which is common among people diagnosed with lung cancer that was removed surgically. But today she’s excited by scientific advances in resectable lung cancer focused on helping more patients.

Understanding the patient experience

Shariati said understanding the patient experience is what drives a researcher’s passion, innovation and desire to help others.

article quote image

“It is very important to have that experience in managing and seeing patients because it gives you a completely different perspective on how you conduct your work.”

— Dr. Ayman Samkari

Executive director in oncology clinical development

Each day, Samkari and Shariati continue to push the boundaries in research to help make a difference for people living with cancer.

Health awareness

VIDEO: Patient with PAH shares her clinical trial experience 

Diagnosed with pulmonary arterial hypertension, Colleen Brunetti knows the importance of participating in clinical trials

May 15, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Colleen Brunetti is a wife and a mother of two who lives with pulmonary arterial hypertension (PAH) — a rare disease that affects the pulmonary arteries. She’s passionate about helping others affected by PAH and focused on helping the medical community by participating in clinical trials.

Patient volunteers like Brunetti are central to the success of clinical trials. Diverse participation is essential as different people may have different reactions to the same treatment, based on their age, gender, weight, race, ethnicity, lifestyle or severity of illness or disease.

“I'm acutely aware that without clinical trials, we don't move forward.”

— Colleen Brunetti

Participating in a clinical trial requires a supportive team

In addition to her doctors, Brunetti’s family is a key part of her support team. She said it’s vital to be open and understanding of the impact clinical trial participation may have not only on yourself, but also those around you. She added that talking, asking questions and learning more about the benefits and risks of a clinical trial is critical.

“We work as a team together to decide if a clinical trial, or anything that I need, is in my best interest,” she said. “No matter what you go through, there’s going to be changes. Having heart-to-heart conversations about what that looks like and what might need to be adjusted is really important.”

What Brunetti considered when joining a clinical trial

Brunetti said she encourages anyone considering joining a clinical trial to understand that “your doctor has to be your teammate.” She said questions will come up, like:

  • Will I receive the medicine or the placebo?
  • What kind of side effects might I anticipate?
  • How am I going to manage this?
  • What happens if there’s an emergency?

“If it’s not for you, that’s OK,” she said. “But if you can, I would encourage people to jump in with eyes wide open.”

Why it’s so important to participate in clinical trials

Clinical trials are research studies with volunteers designed to learn more about how our bodies respond to medicines, vaccines, medical devices or other treatments. It may take many clinical trials to understand which treatments work and how they work.

Innovation

Our Q1 2023 earnings report

April 27, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

MSD’s Q1 2023 results reflect continued strong underlying performance across key growth drivers, particularly in oncology and vaccines. Our company announced Q1 worldwide sales of $14.5 billion.

“Inspired by our commitment to bring bold science forward to address critical unmet patient needs, we began 2023 with significant advancements across our innovative pipeline,” said Robert M. Davis, chairman and chief executive officer, MSD. “Our first-quarter results are a reflection of the focused execution of our science-led strategy, strong performance across our key growth drivers, continued momentum commercially and operationally, and — most importantly — the collective and dedicated efforts of our colleagues around the world. I’m proud of the progress we’ve made, and we will continue to move with speed and agility to deliver value for patients and shareholders, now and well into the future.”

MSD anticipates full-year 2023 worldwide sales to be between $57.7 billion and $58.9 billion.

Take a look at the infographic below for more details on Q1 2023 results.

Download infographic

MSD Q1 2023 infographic
Innovation

Individualized neoantigen therapies: exploring one medicine for one patient

Scientists are researching new ways to help train the immune system to fight cancer

April 13, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Over the past decade, immunotherapy has transformed our understanding of how the immune system can be used to help fight some types of cancer. However, for the last 50 years, scientists have been researching how we could potentially use vaccines to treat cancer — another investigational approach to harness the immune system to help recognize and destroy cancer cells — with little success.

Now we’re looking at a potential therapy that is building upon the learnings of immunotherapy trials from the past and incorporating that into an individualized cancer approach that’s specific to a patient’s own tumor. Researchers are currently exploring the potential of individualized neoantigen therapies to help fight cancer.

Cancer research is becoming more personalized

Cancer is a result of the body’s own cells undergoing mutations which create abnormal proteins in cancer cells, known as neoantigens, that are not usually seen in normal cells. These mutations are unique to each person’s tumor, so that’s one of the reasons why patients who have been diagnosed with the same type of cancer and who have received the same type of treatment may have different responses.

As the treatment of cancer continues to evolve and advance, researchers are focusing on more individualized approaches. This includes a new area of research into individualized neoantigen therapies that use information from a person’s tumor biopsy sample to help develop a therapy unique to their tumor’s mutations.

MSD's Dr. Jane Healy

“This area of research has really captured our imagination of what’s possible in the development of cancer therapeutics.”

  • Dr. Jane Healy
    Vice president and head of oncology early development at MSD Research Laboratories

In collaboration with Moderna, we’re studying this area of research in an effort to advance more individualized approaches to help improve outcomes for people living with cancer.

Learn more about individualized neoantigen therapies

MSD PVC Infographic
Our people

VIDEO: Here for Good – When passion and curiosity fuel innovation

Hear how one of our scientists balances her work and family life to accelerate our groundbreaking research

February 3, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Testing experiments in a lab can be a lot like raising kids. Sometimes your molecules do what you want them to do, and sometimes they don’t. But it’s a challenge Denarra Simmons, a senior scientist at MSD and a mother of two, is always up for.

“You’re constantly trying to find other medicines because all medicines don’t work the same way for all people,” Simmons said.

“You spend the long nights thinking about experiments, how to make things better, how to move things faster to help more people.”

— Denarra Simmons

Denarra Simmons working in a lab

Simmons has been curious about how and why things work for most of her life. As a young child, she peppered her family with questions, trying to understand the “why” behind anything and everything. But it wasn’t until a man in a lab coat came to her grade school to talk about his career that she realized what her true passion was.

“He wrote an equation on the board and was talking about how people made medicines, and I thought that was fascinating,” Simmons said. “But the thing that really drew my attention was how excited he was when he was explaining what he did. I wanted to do something that I would love that much and over time, I realized that for me, it was science and helping people.”

For 12 years, Simmons has funneled that passion into her research at MSD. Simmons works in drug development to test the efficacy and safety of our biologic medicines used for investigational new drug (IND) enabling studies.

“Working in the lab is my favorite part of my job — and getting good data."

Denarra and her family

Some days in the lab may be more successful than others, and Simmons uses it all to show her children what it takes to be a scientist. “Good days are celebrated, and the tricky days, we keep working towards improving,” she said.

Simmons also feels strongly about teaching her children that there’s more to life than work.

“I’m always thinking about the experiments, but when I’m home with the children, I really try to give them the attention and time they need,” she said.

But once her daughter and son finish their homework and head to bed, Simmons finds herself thinking about her next set of experiments.

“When you find out a medicine you worked on has helped so many people, you feel really special and you know all the work has been worthwhile,” she said. “And that’s why you’re doing what you do: you’re making a difference in society.”

Our people

In Burkina Faso, a personal mission to make a difference in one community

MSD colleagues found non-profit to provide critical resources for a village in one of the poorest countries in the world

November 28, 2022

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Challenging life experiences united two MSD colleagues — Jules Millogo and Cathy Hoath — on a mission to create opportunities and break the cycle of poverty in the small village of Konkourona, in the West African country of Burkina Faso.

Homelessness, hunger and illness in Konkourona

Konkourona is where Millogo, director, medical affairs, global vaccines, grew up with extremely limited access to health care, education, clean water and the bare necessities. It’s also where he witnessed six of his siblings pass away from preventable diseases. Millogo’s father was a strong believer in education and sent him to attend the nearest school in another village, which was hours away from Konkourona on foot.

Despite experiencing much communal trauma growing up, Millogo graduated from medical school and began his career in a Burkina Faso province far from Konkourona, serving as the only doctor for a population of 250,000.

“I somehow managed to overcome bouts of homelessness, hunger and illness from infectious diseases that often come with extreme poverty,” said Millogo. “I grew up knowing that I needed to make a difference in Konkourona and bring opportunities and hope to the people living there.”

Forming Konkourona Alliance Foundation (KAFO) to fight for opportunity and equity

When Millogo joined MSD, he met Cathy Hoath, senior director of regulatory affairs international, vaccines. Hoath was born in Booth Memorial Hospital for Unwed Mothers in Philadelphia, after her teenage birth mother was thrown out of her parents’ home and was unable to find a job or apartment. That experience fuels Hoath’s drive to fight for equity and opportunities — for women, children and all who want to create better lives for themselves and their communities in the U.S. and around the world.

In 2019, during a meeting with the World Health Organization to register our company’s Ebola Zaire vaccine in the countries at highest risk in Africa, Millogo and Hoath began discussing ways they could support development in Konkourona. A few months later, they co-founded the non-profit organization Konkourona​ Alliance Foundation (KAFO), Inc.

“It was the perfect convergence of my professional and personal worlds, giving me the chance to fight for greater opportunity and equity for some of the world’s most vulnerable people.”

  • Cathy Hoath

Because remote villages like Konkourona are often referred to in development efforts as “the last mile,” they named their effort “The First Mile Development Program.”  The people of Konkourona are KAFO’s highest priorities.

KAFO builds foundation for education

Millogo and Hoath have met many like-minded people — both within our company and beyond — who have become supporters of KAFO since its founding. And they’ve made good progress in Konkourona.

children in Konkourona sitting in new classroom

New classroom with desks and textbooks for each child

KAFO has built three new classrooms — reducing class sizes from approximately 90 to 45 students — as well as an office and housing for teachers. It also renovated an existing building for use as a library.

Approximately 400 students are now receiving assistance, from books and tutoring to tuition and bicycles so older students can make the two-hour journey to the closest upper-level school.

Students are making educational progress

Previously, only one or two students per year progressed to middle school. Now, in just a couple of years, over 80 students are continuing their education at middle school and beyond.

“In 2020, we began providing books for each child because there were not nearly enough. We also opened the school at night — the only place in the village with electricity — and offered tutoring services. That year, 20 children passed the middle school entrance exam — which is unheard of in any school in this sub-region,” said Hoath. “In the past two years, 63 additional students have progressed to middle school.”

Eric, a standout student in Konkourona, Burkina Faso

Eric is a mentor to the younger children and a role model for what can be achieved with an opportunity and hard work.

One of those students is Eric, who couldn’t afford tuition for middle school. His father died, and he had to help his mother, so he got a job on Millogo’s brother’s farm. Now, through KAFO’s sponsorship, he’s going to high school. He’s also helping to sustain the program long term by mentoring younger children and working with the team on the ground to secure books and bicycles.

He’s now thinking about what he may want to study in college — a dream that would not have existed just several years ago.

“We have high hopes for this thoughtful young man,” said Millogo.

Improving access to health care and clean water

The maternal and child mortality rates in Burkina Faso are among the highest in the world. In addition to a lack of health care resources, the villagers also had very little access to clean water.

“One of the biggest problems we face in Konkourona is water-borne diseases,” said Millogo. “People drink water from wherever they can find it — open ponds or other sources contaminated with human and animal waste and other pathogens.”

Little boy in Konkourona with water pot

Clean water is now widely available for drinking and washing

Working closely with the Mami Siara Na Association, a community-led organization created in 2019 to partner with KAFO to lead and sustain development efforts on the ground, the team has now constructed three water towers, three community fountains, a health center for mothers and children, a separate facility for primary care, a pharmacy, latrines, housing for health care workers and an incinerator.

“Providing access to clean water in Konkourona is practically a revolution.”

Jules Millogo

“And the health care facility, where we can provide critical maternal care, immunizations, and primary services for children and community members — like caring for illnesses, wounds, etcetera — will have a significant impact for this community in many ways,” said Millogo.

Providing economic development and hope for a better future

New pharmacy in Konkourona, Burkina Faso

Konkourona’s new — and first — pharmacy

The improvements in education and health care have sparked local economic development as well. There are new jobs in Konkourona to ensure continued access to education, health care, water and sanitation, not to mention those related to construction activities.  

Over the next five years, Millogo and Hoath plan to build a middle school, a technical school and a high school, as well as housing for teachers in these schools. They also plan to expand the health center.

“We’re all in on this program and learning every day how to do new things — things we don’t have experience in — to make progress in Konkourona,” said Millogo. “We’re fortunate that we’ve received so much support from so many people to help make these important visions a reality. And, we’re just getting started.”

Learn more about Konkourona Alliance Foundation – Empowering a Village and how you can help sponsor a child.

Previous
Next
  • In Burkina Faso, a personal mission to make a difference in one community
  • KAFO-funded health center in Konkourona, Burkina Faso
  • Villagers celebrate opening of health center in Konkourona, Burkina Faso
  • Jules Millogo of KAFO at celebration of new health center in Konkourona
  • New latrine in Konkourona, Burkina Faso
  • Librarian at new library in Konkourona, Burkina Faso
  • In Burkina Faso, a personal mission to make a difference in one community
  • Mother and child on bicycle in Konkourona, Burkina Faso
  • 3 acquaintances smile together in clothing store
Previous
Next
  • Millogo plants one of the 1,100 native shade and fruit trees KAFO donated to provide an alternate food source and replenish what has been lost over the past few decades.
  • Worker sets up almost $500,000 of equipment and supplies in one of the new health center buildings. Green barriers surround two of the 1,100 trees KAFO planted earlier in the year as part of a reforestation effort.
  • Villagers celebrate the opening of the new — and first — health center.
  • At a celebration for the new health center, Millogo expresses gratitude to the people all over the world who are helping support KAFO's efforts in Konkourona.
  • New latrines built around the health center will help keep the environment clean by encouraging people to transition toward better sanitation.
  • The librarian in Konkourona's first library talks about the variety of books are now available to villagers. Previously, the only type of book available in the village was a small supply of textbooks.
  • Konkourona consists of roughly 4,000 subsistence farming inhabitants, who use nearly all crops or livestock to maintain the farmer and the farmer's family. This farmer is milling grain for storage.
  • Walking is the primary form of transportation in the village, but the fortunate families have bikes. Through sponsorships, students now have access to bikes to make the two-hour journey to upper level schools in other villages.
  • Donations from Care and Share Thrift Shoppes will help hundreds in Konkourona (left to right: Sarah Bergin, executive director of Care and Share Thrift Shoppes, Hoath and Millogo)

Sustainability

Accelerating global access

Our company is collaborating with a range of partners to enable access for patients around the world

September 8, 2022

Share this article

.st0{fill:#00857C;}

article hero thumbnail

At the outset of our research efforts for COVID-19, our company made clear its commitment to make any vaccine or medicine we develop for this pandemic broadly accessible.

Here’s how we have been working to fulfill that commitment:


Download the infographic